On 27 February 2026, US Department of Health and Human Services Secretary Robert F. Kennedy Jr. announced — on The Joe Rogan Experience, episode #2461, rather than in the Federal Register — that roughly 14 of the 19 peptides the FDA had restricted from pharmacy compounding in 2023 were being moved back from Category 2 to Category 1. BPC-157 is on that list. It is one of the most closely watched regulatory developments in the peptide space this year, and it is worth being precise about what has actually changed versus what has not.
How BPC-157 Ended Up in Category 2
In 2023, the FDA placed BPC-157 and eighteen other bulk drug substances into "Category 2" under Section 503A, a status that effectively barred licensed compounding pharmacies from preparing individualized prescriptions with it, citing insufficient safety data to support compounding at scale. The practical effect was not to eliminate demand — it redirected patients and clinicians away from regulated pharmacy channels and toward unregulated online sellers, a dynamic Kennedy referenced directly in the February announcement as part of the rationale for revisiting the list.
What Has Actually Changed — and What Hasn't
As of the announcement, the FDA had not yet formally published a revised Category 2 list. A podcast statement from the HHS Secretary is a strong signal of policy direction, not a rule. Until the agency publishes the update, compounding pharmacies remain unauthorized to prepare BPC-157 under a physician's prescription. For that regulated clinical pathway, the reclassification is expected but not yet procedurally live.
For the research-use channel — where laboratories source reference material for in-vitro and preclinical work — this development changes essentially nothing operationally. Category 1 and Category 2 status governs whether a 503A compounding pharmacy may prepare a compound for a named patient under prescription. It has no bearing on the separate framework that governs analytical and laboratory-grade research chemicals.
What This Reclassification Does Not Mean
- It is not FDA approval. Approval requires completed clinical trials and a New Drug Application; BPC-157 has neither.
- It does not validate research-use-only sourcing for anything other than laboratory and in-vitro work.
- It does not make self-administration outside clinical supervision appropriate — the evidentiary picture for human use remains, in the FDA's own framing, preliminary.
- It does not open the door to over-the-counter or direct-to-consumer medical sale, which remains prohibited regardless of Category status.
Why It Matters for the Underlying Research
The policy debate is about pharmacy access, but the scientific questions researchers actually care about — batch-to-batch purity, structural stability, and independent HPLC/MS verification — are untouched by it. If anything, renewed regulatory and media attention on BPC-157 makes reagent integrity more important, not less: a compound under this much public scrutiny is also a compound where confounded or under-verified data gets picked apart quickly. Readers interested in the biochemical mechanisms behind the current interest in BPC-157 — the FAK-paxillin and VEGFR2-Akt-eNOS signalling pathways implicated in tissue-repair modelling — can find the underlying pathway analysis in our earlier deep-dive on tissue repair signalling in BPC-157 and TB-500.
For laboratories that need traceable, third-party-tested material for that kind of work, sourcing standards matter more during a period of regulatory flux, not less. That is the standard we hold our own peptides Australia researchers rely on, regardless of which way a compounding rule moves in the United States.
Disclaimer: This article summarises publicly reported US regulatory developments for general informational purposes only. It is not legal, medical, or regulatory advice, and it does not describe or promote any compounded, prescription, or human-use product. 10KITSM does not sell compounded pharmaceuticals. All compounds referenced are supplied strictly for laboratory and in-vitro research use, are not for human or veterinary consumption, and readers with questions about regulatory status in their own jurisdiction should consult a qualified professional.